Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1984 1
1989 2
2006 1
2007 1
2008 4
2009 7
2010 1
2011 3
2012 5
2013 2
2014 6
2015 1
2016 2
2017 2
2018 3
2019 1
2020 3
2021 3
2022 7
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial.
Rizas KD, Freyer L, Sappler N, von Stülpnagel L, Spielbichler P, Krasniqi A, Schreinlechner M, Wenner FN, Theurl F, Behroz A, Eiffener E, Klemm MP, Schneidewind A, Zens M, Dolejsi T, Mansmann U, Massberg S, Bauer A. Rizas KD, et al. Among authors: krasniqi a. Nat Med. 2022 Sep;28(9):1823-1830. doi: 10.1038/s41591-022-01979-w. Epub 2022 Aug 28. Nat Med. 2022. PMID: 36031651 Clinical Trial.
Radiotheranostic Agents in Hematological Malignancies.
Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K, Krasniqi A, Lejeune M, Withofs N, Devoogdt N, Dumoulin M, Karlström AE, D'Huyvetter M. Caers J, et al. Among authors: krasniqi a. Front Immunol. 2022 Jul 5;13:911080. doi: 10.3389/fimmu.2022.911080. eCollection 2022. Front Immunol. 2022. PMID: 35865548 Free PMC article. Review.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: krasniqi a. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
Injuries related to sauna bathing.
Kaiser P, Seeher U, Krasniqi A, Keiler A, Crazzolara R, Meryk A. Kaiser P, et al. Among authors: krasniqi a. Injury. 2023 Jul;54(7):110825. doi: 10.1016/j.injury.2023.05.056. Epub 2023 May 19. Injury. 2023. PMID: 37211472 Free article.
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, Lecocq Q, Ceuppens H, De Vlaeminck Y, Awad RM, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K, Krasniqi A. Ertveldt T, et al. Among authors: krasniqi a. Mol Cancer Ther. 2022 Jul 5;21(7):1136-1148. doi: 10.1158/1535-7163.MCT-21-0791. Mol Cancer Ther. 2022. PMID: 35499391 Free PMC article.
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, Mey W, Lecocq Q, Vlaeminck Y, Awad RM, Goyvaerts C, Veirman K, Morgenstern A, Bruchertseifer F, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K. Ertveldt T, et al. Among authors: krasniqi a. J Nucl Med. 2023 May;64(5):751-758. doi: 10.2967/jnumed.122.264752. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055223 Free article.
61 results